Meet the team
Founded in 2021, ADMIR is a deep tech start-up bridging the gap between infrared R&D and end-users doctors and biologists. We design, develop and manufacture mid-infrared spectral imaging systems, as well as deep-learning softwares dedicated to data analysis.
Our team encompases optical physicists, biologists, data scientists and deep-learning experts.
Direction board
Laurent Duraffourg
CEO & Co-founder
Laurent holds a PhD in physics focused on quantum cryptography systems and photon-counting integrated circuits. He began his career at PHS MEMS (startup, Grenoble) as a research engineer in MOEMS. In 2004, he joined CEA as a permanent researcher and earned his research supervision accreditation (HDR) in 2010. Laurent is Director of Research. From 2011 to 2014, he co-led the CEA – CALTECH alliance on Large-Scale Integrated Nanosystems (NEMS-VLSI). He later headed the Optical Sensors Lab (30 staff), advancing mid-infrared photonics, and then led the Microsystems Division at CEA-Leti (115 staff). Laurent has authored 110+ publications, filed 35+ patents, and published two books.
Mathieu Dupoy
CTO & Co-founder
An engineering graduate from PHELMA, Mathieu began his career at Photline Technologies (startup), a pioneer in LiNbO₃ electro-optic modulators for telecom. In 2006, he joined the CEA-Leti/bioMérieux joint team, developing rapid microbial detection methods using fluorescence microscopy, light diffraction, ombroscopy, and Raman spectroscopy. Since 2015, he has led multispectral infrared imaging projects for biological applications at CEA. He holds over 17 patents and has contributed to 25+ scientific publications in bio-optics and medical imaging.
Philippe Andreucci - Chairman & Co-founder
Philippe Andreucci
Chairman & Co-founder
A graduate of CentraleSupélec and ESSEC Business School, Philippe began his career in innovation marketing at CEA and in an SME, before managing R&D programs in nanotechnologies. He has initiated several strategic international collaborations between world-renowned research institutions and later turned to entrepreneurship, launching breakthrough technology-based products. He founded and grew a 30-person company with over €3.5M in revenue by the end of 2022. He also relaunched deeptech initiatives in medical devices and instrumentation—most notably as CEO of InjectPower.
Frédéric Staroz
CMO & Partner
Frédéric is a medical doctor specialized in anatomical and cytological pathology, with a postgraduate degree (DEA) in the fundamental basis of oncogenesis. He joined ADMIR as the originator of the MIRSTAIN concept, while continuing his clinical practice at OuestPathologie. He currently serves on the board of the French Society of Pathology (SFP), where he led the VisioMel data challenge project, supported by the Health Data Hub and funded by Bpifrance. This large-scale histology slide digitization project directly inspired the development of MIRSTAIN.
Scientific and advisory board
Pr. Pierre Saintigny
Oncologist, Centre Léon Bérard
Pierre Saintigny is a medical oncologist and physician-scientist at Centre Léon Bérard in Lyon, heavily involved in the development of translational research programs. He is affiliated to the Department of Medical Oncology, to Alain Puisieux’ team (EMT and Cancer Cell Plasticity) at Cancer Research Center of Lyon and to the Department of Translational Research and Innovation where he is the Director of the Laboratory of Translational Research and coordinates the Unit of Tumor Characterization. He is focusing his research on the lung and head and neck field. He is actively involved in the large scale sequencing program AURAGEN in the context of Plan France Médecine Génomique 2025.
Eric Postaire
Pharmacist, Académie des Sciences
Éric Postaire, a pharmacist and Doctor of Science, is a member of the French National Academy of Pharmacy and a Chevalier of the Order of Academic Palms. As a hospital pharmacist and Associate Professor at the University of Paris Sud, he advanced clinical pharmacy and therapeutic research, particularly in hemodialysis, nutrition, and medical devices, while also establishing links between oxidative stress and immune function through basic research. In 1994, he co-founded Ar2i, now Neovix Biosciences. At Inserm (2003–2007), he led the development of national clinical research infrastructure, including biobanks and clinical trial networks. Since 2010, he has served as advisor to the Secrétaires perpétuels of the French Academy of Sciences.
Pr. Erik Goormaghtigh
IR Spectroscopy Researcher, Université Libre de Bruxelles
Pr. Erik Goormaghtigh is a leading European expert in FTIR spectroscopy of biological molecules, cells, and tissues, with over 250 peer-reviewed publications, more than 10,000 citations, and an h-index of 54. Over the past two decades, he has focused on cancer research using FTIR spectroscopy, analyzing millions of spectra from cultured cells and tumor tissues in collaboration with hospitals in Belgium, France, and Switzerland. He has developed tools and methodologies central to these studies, resulting in numerous publications and patents. Academically, he has served as Research Director with the Belgian National Fund for Scientific Research, Professor at ULB, President of the Chemistry Department and a doctoral school, and co-director of the Center for Structural Biology and Bioinformatics.
Henri Porte
Vice President of ixBlue
Henri Porte is Vice-President of the Photonics activity of the iXblue group. With a scientific background, he obtained a PhD in optics and signal processing from the University of Besançon in 1985. He then joined the CNRS (French National Center for Scientific Research) as a researcher at the PM Duffieux Optics Laboratory. He developed a research activity in the field of optical modulators based on lithium niobate. In 1998, as CNRS Research Director, he participated in the creation of the Franco-American Laboratory “GTL-CNRS-Telecom” in Metz, in partnership with Georgia Tech of Atlanta University. In 2000, he founded Photline Technologies in Besançon and became its CEO. In 2014, Photline joined the iXblue group. Today, he is the Deputy Managing Director. Henri Porte has published more than 150 articles in scientific journals and international conferences, he is co-inventor of eighteen patents, and has directed a dozen thesis.
Christian Sarbach
CEO NeoVix Biosciences
Pharmacist, PhD in analytical chemistry and former Paris Hospital’s Intern. After a first industrial experience as Chief of Quality Control Laboratory at Johnson & Johnson (Val de Reuil, France), Christian Sarbach founded in 1994 AR2i, CRO involved in R&D in Analytical Chemistry, Quality Control of pharmaceutical products, and Regulatory Affairs consulting. He is now CEO and Qualified Person of AR2i. CS is also President of Neovix Biosciences group, involved in the support of pharmaceutical and cosmetic laboratories for Development, Regulatory, Quality and Compliance of Computerized Systems.
